leisure time -WSS

leisure time

author：explore 2025-09-29 12:01:10 - browse：589

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Travel bans should be based on evidence, not politics or fear

WSS

Home health providers sue Medicare over payment cuts

ACA's risk program benefits Blue Cross Blue Shield insurers

Biden’s NIH nominee is languishing in Congress

Pandemic and All Hazards Preparedness Act needs lean update

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Wegovy cuts risk of cardiovascular events by 20%, study finds

entertainment

leisure time

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Home health providers sue Medicare over payment cuts

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Sage's campaign to raise awareness of postpartum depression hits a nerve

Jerome Adams on the need for new antivirals for Covid

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Sports medicine is finally prioritizing gender equality

Hospitals use virtual reality to design more inclusive rooms for kids

In age of alternative facts, a scholarly course on calling out crap

Pandemic and All Hazards Preparedness Act needs lean update

hotspot

Choosing scientific sides in the fight against Alzheimer's

Lessons Learned: This is why you network to find that industry job you want

Biden praises World Series champion Astros for impact off the field during White House celebration

Former Georgia lieutenant governor says he received grand jury subpoena

The painfully weak evidence on taking collagen to treat arthritis

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

entertainment

explore

knowledge

focus